Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
bamlanivimab
Pharma
Use of banned antibodies remained ubiquitous this winter
The U.S. FDA earlier this year put the kibosh on a pair of monoclonal antibody combo therapies from Eli Lilly and Regeneron. Did states listen?
Fraiser Kansteiner
Sep 2, 2022 9:50am
Lilly's Olumiant gets full FDA nod for COVID patients on oxygen
May 11, 2022 8:50am
With mAbs ineffective vs. subvariant, FDA limits GSK/Vir drug
Feb 24, 2022 9:35am
Lilly wins FDA approval for yet another COVID-19 antibody drug
Feb 11, 2022 5:42pm
Lilly scores $720M deal with U.S. for latest antibody treatment
Feb 11, 2022 8:52am
Amgen's COVID-19 deal with Lilly helped amid drug slowdown
Feb 7, 2022 6:14pm
